UmbriaExplore our travel guides. Share your stories, tips and questions on Reddit.
Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
This stopped being a clinical-catalyst story in November 2025 and the page has to say so. Between then and September 2026 the European marketing application was withdrawn, the chief executive was terminated for Cause, the auditor reversed its own opinion on internal controls, two quarterly reports were filed late, a proxy contest was fought and a new securities class action was announced. There is no regulatory decision pending anywhere: in the United States blarcamesine has an investigational new drug application opened in March 2026 and nothing more. What is left is $118.3 million of cash, no debt, and a Phase 3 that has not started.
Get every Merlintrader report in real time on Telegram: join @merlintraderpub_com.
Anavex’s fiscal year ended on September 30, 2026, so the annual report is due by December 29 for a non-accelerated filer; last year’s was filed on November 25. There is no clinical readout scheduled, so this is the nearest dated event that can move the file. The question it answers is not earnings. On August 28, 2026 the company amended its fiscal 2025 annual report to report that internal control over financial reporting was not effective, and Grant Thornton reversed its own prior opinion in writing: “our present opinion… is different from that expressed in our previous report.” The stated cause, verbatim: the company “did not maintain effective Control Environment and Information and Communication elements of the COSO framework as the former CEO failed to set an appropriate tone at the top, including lack of transparency with the Board regarding regulatory, clinical and non-financial matters.” Whether that is reported as remediated at September 30, 2026 is the binary in December. No financial statements were restated.
The sequence, from the filings. November 2024: marketing application submitted under the centralised procedure for early Alzheimer’s. December 2024: accepted for scientific review. November 14, 2025: negative trend vote after the oral explanation — the shares fell 35.9 per cent that day, from $5.69 to $3.645 on 23.0 million shares. December 2025: formal negative opinion adopted; re-examination requested. March 25, 2026: application withdrawn before the re-examination completed, “following feedback from the EMA’s CHMP indicating that it would not be in a position to issue a positive opinion” — shares down 34.6 per cent to $2.74. June 2026: the committee published a withdrawal assessment report concluding the overall benefit-risk was negative and recommending refusal of a conditional authorisation, and separately adopted scientific advice on the design of a future Phase 3. A European Phase 3 “is not being pursued at this time.” Any 2026 write-up giving a committee opinion date is recycling the pre-November-2025 timeline.
The balance sheet is the case. $118.3 million of cash and no debt of any kind against a market value of $187 million means roughly $69 million of enterprise value for a company with four designated programmes and a decade of clinical data. There is no going-concern language and no substantial-doubt conclusion. The listing deficiency was procedural and was cured on September 2, 2026. The old Rett class action was dismissed and the dismissal was affirmed on appeal in June 2026, and both derivative suits were dismissed in August. Rett syndrome carries Orphan, Rare Pediatric Disease and Fast Track designations with an approved adult Phase 3 protocol, the FDA has granted a meeting to discuss adding paediatric patients, and the European committee has already given written scientific advice on the design of a new Alzheimer’s Phase 3. Short interest at 15.5 per cent of the share count and 25 days to cover is a crowded position in a name with $118 million of cash.
There is no application pending, no Phase 3 running, no permanent chief executive, no chief financial officer with that title and no chief medical officer. The pivotal Alzheimer’s trial’s co-primary functional endpoint failed at P=0.357, and the company’s own quarterly report records the regulator’s finding that the significant cognitive result came from a model changed after the study was unblinded and was therefore “a post-hoc analysis that could not render the failed study successful.” The paediatric Rett trial missed. The auditor has reported an adverse opinion on internal controls naming tone at the top. The terminated chief executive is in arbitration seeking severance, accelerated equity and damages for defamation, and has filed derivatively against four directors. Winning the proxy contest triggered change-of-control acceleration, so every unvested award in the company vested on September 24 — including performance awards whose milestones were never met.
Most of what circulates about this company describes a pending European decision, a trial that met its primary endpoint, and a Fast Track designation in Alzheimer’s. None of the three is the current record. The application was withdrawn in March 2026 and the committee has published a recommendation to refuse it. The trial’s co-primary functional endpoint failed, and the analysis behind the cognitive result was changed after unblinding — a point the company now reports against itself in its own filing. The Fast Track and Orphan designations are Rett syndrome and Fragile X, not Alzheimer’s, where there is an investigational filing and nothing else. This page sets out what is actually filed, what the money looks like, what the governance year did to the share count, and what the next dated event is.
Anavex Life Sciences is a clinical-stage company with no approved product and no revenue. The central question for the next 12–18 months is whether blarcamesine regains a dated path to a filing: the European application was withdrawn March 25, 2026, and the United States has an investigational new drug filing only. Cash was $118.3 million at June 30, 2026, with no debt, against a June-quarter burn of about $3.0 million a month. What decides it is a Phase 3 start and whether the annual report due by December 29 reports internal controls remediated. Source Source
Reported by the firms rather than by the company, and not verified at docket level here: a securities class action said to have been filed in the Southern District of New York, first announced on September 29, with a class period of November 26, 2025 to August 28, 2026 and a lead-plaintiff deadline of November 30, 2026. The alleged failure is disclosure of inadequate internal controls and of regulatory risk arising from the former chief executive’s conduct. Note the period’s endpoints: it opens the day after the fiscal 2025 annual report was filed and closes the day the amendment and the two late quarterly reports were filed. No Anavex filing mentions it.
All six company nominees were elected and none of the six dissident nominees came close — the best received 14,469,637 votes for against 21,046,035 against. But 31.7 per cent of votes cast were withheld from the board chair and 25.5 per cent from the audit-experienced director. And because three directors were first elected “in connection with an actual or threatened proxy contest,” they do not count as incumbent, which satisfied the board-change test under all three incentive plans: every outstanding unvested award in the company immediately vested. The dissident held 337,663 shares, about 0.36 per cent of the company.
The agency “has granted the Company’s request for a meeting” to discuss adding paediatric patients to the adult Rett syndrome Phase 3. A granted meeting is not an agreed amendment, and no meeting date is public. The adult study itself, about 170 participants randomised one to one, over a double-blind period the company gives as twelve weeks in its June quarterly report and sixteen weeks in its August 25 release, has an approved protocol but has not been registered on the public trial registry and has no disclosed start date.
In one day: the amended fiscal 2025 annual report stating that internal control over financial reporting was not effective, with Grant Thornton withdrawing its earlier unqualified opinion; the amended December-quarter report on the same basis; and the two late quarterly reports, for the March and June quarters. The cause given is the former chief executive’s failure “to set an appropriate tone at the top, including lack of transparency with the Board regarding regulatory, clinical and non-financial matters.” No numbers were restated. The filings also cured the exchange’s late-filing deficiency, and compliance was confirmed on September 2.
How robust or fragile the company looks over the next twelve to eighteen months, scored 1 to 5 across five weighted pillars. Assessed on October 1, 2026, on market data to the September 30, 2026 close.
| Balance sheet and runway · 30% | 4.0 / 5 | $118.3 million of cash at June 30, 2026, up from $102.6 million at the September 2025 year end. No borrowings of any kind, no convertibles, and no multi-year lease — the office lease has an initial term of twelve months or less, so there is no lease liability at all. Working capital $112.4 million against $7.7 million of current liabilities. No going-concern qualification and no substantial-doubt conclusion. Against that: the June quarter burned about $9.1 million, roughly $3.0 million a month against a nine-month average of $2.30 million, and the company cut its own runway guidance from “more than 3 years” in February to “mid to late fiscal 2028” in July. |
| Catalyst · 30% | 1.0 / 5 | There is no application pending anywhere, no trial enrolling, and no clinical readout scheduled. The nearest dated event is the fiscal 2026 annual report, due by December 29, whose news value is an accounting opinion rather than a result. Three items guided for September 2026 — a drug-interaction study completion, a Fragile X investigational filing and a date for the FDA meeting granted on September 9 — are all unconfirmed. The adult Rett Phase 3 has an approved protocol, no start date and no registry entry; the Alzheimer’s Phase 3 is at the design stage. |
| Dilution · 20% | 2.5 / 5 | Two-year dilution is only about 9.3 per cent, almost all of it in a single quarter, and the share count has moved by 25,084 shares since December 2025. There are no warrants at all, and the entire options book of 8,982,250 shares at a $6.45 average strike is far out of the money against $2.02, with aggregate intrinsic value of $149,304. Against that: $103.2 million of at-the-market capacity remains unused on a $187 million company, and the company states it will be unable to sell under the agreement at all once it files its next annual report, having lost Form S-3 eligibility through the late quarterly filings, and 14,007,678 shares of unissued plan capacity sit behind the options book. |
| Liquidity · 10% | 3.0 / 5 | 2,965,136 shares traded on September 30 against a three-month average of 899,815 — 3.3 times — so depth appears when there is news. Institutional ownership is 46.65 per cent across 222 holders, net sellers over the period. The complication is the short side: 14,333,378 shares short at the September 15 settlement date, 15.46 per cent of the share count and 25.1 days to cover. That is a crowded and slow position, which amplifies how any headline reaches the price in both directions. |
| Execution · 10% | 1.0 / 5 | The chief executive was terminated for Cause on April 30, 2026 and is now in arbitration seeking severance, equity acceleration and damages for defamation, and suing four directors derivatively, with the company unable to estimate a range of loss. The auditor reversed its own opinion to report internal controls not effective, naming the former chief executive’s failure to set tone at the top. Two quarterly reports were filed late. A chief operating officer lasted ten weeks. There is no permanent chief executive and no chief medical officer. Nearly a third of votes cast were withheld from the board chair. Winning the proxy contest vested every unvested award in the company, performance awards included. No insider bought a share in 2026. |
This is not an indication to buy or sell. It is a description of financial and operational robustness, not a rating, a target price or a recommendation, and it says nothing about whether the shares are worth their price.
The full deep dive has the answer’s building blocks: cash, dilution, catalysts and risks, every figure sourced.
Free. No signup. You decide, we don’t recommend.
These are reading frames, not forecasts, and none of them is a recommendation. Each is written so that a reader can say which document would confirm or break it.
| Scenario | What it assumes | What would confirm it | What would break it |
|---|---|---|---|
| Bull | The market is pricing the governance year and ignoring the balance sheet. $118.3 million of cash and no debt against a $187 million market value leaves about $69 million of enterprise value for four designated programmes, an approved adult Rett Phase 3 protocol, written European advice on an Alzheimer’s Phase 3 design, and a decade of clinical data now sitting inside a live US investigational filing. The old litigation is finished. The listing deficiency is cured. A clean fiscal 2026 annual report in December removes the last open accounting question, and a Phase 3 start would put a dated event back on the calendar for the first time since 2025. | An annual report in December reporting internal controls effective at September 30, 2026 with no new material weakness; a first-patient-in and a registry entry for the adult Rett study; a Fragile X investigational filing accepted; and a permanent chief executive appointed. | A second year of adverse internal-control findings, or the Phase 3 still unstarted and unregistered at the annual report. |
| Base | Nothing dated happens for two quarters. There is no application pending, no trial enrolling and no readout scheduled, so the only events on the calendar are a statutory annual report, an arbitration on an unquantified claim, and a class action whose lead-plaintiff deadline is November 30. Cash covers it — the company guides to “mid to late fiscal 2028” — but the burn is rising, not falling, and the guidance itself was cut by roughly a year at the first release published after the chief executive was terminated. The equity trades on the cash, the short position and the news flow around the former chief executive, not on the science. | A quarter or two of filings with no clinical disclosure; a December annual report that repeats the “mid to late fiscal 2028” language; and the at-the-market facility closing with that filing, unused. | Either a Phase 3 start with a funded timeline, or a financing, which would reset the whole arithmetic. |
| Bear | The asset is what the regulator said it was. The pivotal trial’s co-primary functional endpoint failed at P=0.357, and the significant cognitive result came from a model altered after unblinding — the company reports that finding against itself. The paediatric Rett trial missed its co-primary. A new Phase 3 in Alzheimer’s has no start date, no registration and, on the company’s own account, two clinical-pharmacology studies still to finish before a filing is even possible. Meanwhile the chief executive was removed for Cause, the auditor named tone at the top, the terminated chief executive is suing derivatively, and winning the proxy fight vested every unvested award in the company including performance awards whose milestones were never met. | Another adverse internal-control opinion; an arbitration award or settlement with a number attached; a Phase 3 that slips past fiscal 2027; or an equity raise at a price near the current one. | A clean annual report plus a started, registered Phase 3 and a permanent chief executive — which together would make the governance year a closed chapter rather than the thesis. |
What makes this file unusual is that the cash and the story point in opposite directions. A company with $118 million, no debt and no going-concern language is not in financial distress; a company with no application, no enrolling trial, an interim chief executive and an adverse controls opinion has no dated way to prove its asset works. Both are true at the same time, and which one matters depends entirely on whether a Phase 3 starts.
The reading on this page is that the European file is closed rather than pending, that the pivotal Alzheimer’s result does not stand as the company first presented it, that the governance year rather than the science is what moved the stock, and that the cash is real but has nothing dated to be spent on yet. Each of the following would damage that reading, and each is checkable against a document.
None of these is a prediction. They are the observations that would make the rest of this page wrong, listed so that a reader can check them rather than take the reading on trust.
Anavex Life Sciences is a clinical-stage company with no approved product, no revenue, a fiscal year ending September 30, and a market value of about $187 million at the September 30, 2026 close against $118.3 million of cash and no debt. Six facts set the frame.
There is no regulatory decision pending anywhere. The European marketing application for blarcamesine in early Alzheimer’s was withdrawn on March 25, 2026, before the re-examination the company had requested could complete. In June 2026 the committee published a withdrawal assessment report concluding the benefit-risk balance was negative and recommending refusal of even a conditional authorisation. In the United States there has never been a marketing application: there is an investigational new drug filing opened in March 2026, cross-referencing the 2017 Rett filing, and nothing more.
There is no trial enrolling and no readout scheduled. The adult Rett syndrome Phase 3 has an approved protocol — about 170 participants, randomised one to one — but no start date, and no entry on the public trial registry. The Alzheimer’s Phase 3 is at the protocol-discussion stage. Three things guided for September 2026 are unconfirmed at October 1: the last patient visit in the drug-interaction study, the Fragile X investigational filing, and a date for the FDA meeting granted on September 9.
The pivotal Alzheimer’s trial’s co-primary functional endpoint failed. ADCS-ADL came in at P=0.357. The cognitive co-primary is the one that is quoted, and the company’s own quarterly report records the regulator’s conclusion that the model producing it “was not the analysis pre-specified in the study’s protocol or statistical analysis plan” and reflected changes made after the study was unblinded — “a post-hoc analysis that could not render the failed study successful.” Section 04 sets this out in full.
The designations are not where people think. Orphan Drug, Rare Pediatric Disease and Fast Track designations are for Rett syndrome. There is a separate Orphan designation for Fragile X, and one for ANAVEX 3-71 in frontotemporal dementia. In Alzheimer’s there is no FDA designation of any kind.
The governance year, not the science, is what moved the stock. The chief executive was terminated for Cause on April 30, 2026 by a special committee of independent directors. The auditor reversed its own opinion on internal controls in August, naming the former chief executive’s failure to set tone at the top. Two quarterly reports were filed late, triggering an exchange deficiency that was cured on September 2. A proxy contest was fought and won on September 24 — and winning it triggered change-of-control acceleration, vesting every unvested award in the company. A new class action was announced on September 29.
The cash is real and the burn is rising. $118.3 million at June 30, 2026, no borrowings, no multi-year lease, working capital of $112.4 million, and no going-concern language. But the nine-month average burn of $2.30 million a month understates the current rate: the June quarter alone consumed about $9.1 million, roughly $3.0 million a month, and the company cut its own runway guidance by about a year in July.
The one-line version. Strip the governance year away and what is left is a company with $118 million of cash, no debt, four designated programmes, a decade of data, and nothing dated on the calendar to prove any of it. The next event that can move the file is the fiscal 2026 annual report, due by December 29, and the question it answers is about internal controls rather than about the drug. That is an unusual place for a biotech to be, and it is why the equity trades near its cash.
Nothing is filed for approval anywhere in the world. The European application is withdrawn; the United States has an investigational new drug filing opened in March 2026, into which all historic Alzheimer’s data has been submitted. A Phase 3 is at the protocol-discussion stage with the FDA, and the European committee adopted scientific advice on its design in June 2026. No FDA designation of any kind exists in this indication — no Fast Track, no Breakthrough, no Orphan.
Two foundational clinical-pharmacology studies are running because the European assessment said they are prerequisites for approval, and the company states it “anticipate[s] the FDA will have the same requirements.” One is an absorption, distribution, metabolism and excretion study; the other a drug-interaction study whose last patient visit was guided to the end of September 2026 and is unconfirmed. Those two studies are the practical gate on any future filing, and they are rarely mentioned.
Granted: Orphan Drug, Rare Pediatric Disease and Fast Track designations. An approved Phase 3 protocol exists for adults — approximately 170 participants, one-to-one randomisation, with a double-blind period the company states as twelve weeks in its June quarterly report and sixteen weeks in its release of August 25, 2026, followed by safety follow-up. Not granted: the addition of paediatric patients. The company submitted a formal meeting request in August 2026 and the FDA granted the meeting on September 9; it has not agreed to the amendment, and no meeting date is public. The adult study has no disclosed start date and no registry entry as of October 1, 2026.
The history here matters for calibration. The adult Rett study AVATAR, 33 participants, reported in February 2022 that it met all primary and secondary endpoints, with the behaviour questionnaire response at p=0.037. The paediatric study EXCELLENCE, 92 enrolled and 77 analysed, missed: announced January 2, 2024, the co-primary clinical-impression endpoint was not met, and the behaviour questionnaire at twelve weeks came in at −4.61, p=0.063 — an analysis the company itself labels “ad-hoc” in its annual report. The shares fell 35.1 per cent that day.
Granted: Orphan Drug designation. The investigational new drug submission was guided for September 2026 and no filing confirms it was made. One US patent covers blarcamesine in Fragile X, expiring 2040. A submission starts a thirty-day review clock, so a confirmation here would be the cheapest dated event the company could put on the board.
ANAVEX 3-71 holds an Orphan designation in frontotemporal dementia and completed a Phase 2 in schizophrenia in October 2025 that met its primary safety endpoint and reported efficacy only as “encouraging trends” with biomarker support — no significant clinical efficacy was claimed, and the shares did not move. Development is now paused: “further development work will be contingent on additional funding… or the signing of a strategic partnership. It is also possible that we may sub-license.” ANAVEX 1-41 and ANAVEX 1066 carry the same language. The molecule is licensed in, with milestone and royalty obligations attached.
Two indications have quietly left the story: Parkinson’s disease dementia and schizophrenia are no longer named among the core programmes, which the company now gives as early Alzheimer’s, Rett and Fragile X.
The practical summary. One programme has designations and an approved protocol but has not started. One has a designation and an unconfirmed filing. One has a decade of data, no designation, no application and two pharmacology studies to finish first. Three more are paused pending money or a partner. For a company with $118 million in the bank, the constraint on the calendar is not cash — it is that none of these has a date attached to it.
Four results matter, and the gap between how one of them was announced and how it now reads is the single most important thing on this file.
| Trial | Population | Result as announced | Announced | Reaction |
|---|---|---|---|---|
| AD-004, Phase 2b/3 | Early Alzheimer’s; 509 randomised, 462 analysed | “Met primary and key secondary endpoints.” ADAS-Cog −1.85 points, p=0.033; CDR-SB −0.42, p=0.040 | Dec. 1, 2022 | +35.8 per cent the next session, $8.87 to $12.05 on 45.7 million shares against about 4 million normally |
| AD-004, as later published | same 462 | ADAS-Cog13 −2.027, P=0.008; CDR-SB −0.483, P=0.010; ADCS-ADL +0.775, P=0.357 — not significant | 2024–25 | — |
| ATTENTION-AD, open-label extension | 300 rollover patients, delayed-start design | ADAS-Cog13 difference −3.83, P=0.0165 and ADCS-ADL +4.30, P=0.0206 at week 192 | 2024–25 | No isolated single-day move attributable |
| AVATAR, Phase 3 | Adult Rett, 33 participants | “Met all primary and secondary endpoints”: behaviour questionnaire p=0.037, anxiety/mood scale p=0.010, clinical impression p=0.037 | Feb. 2, 2022 | $10.55, down 4.4 per cent on the day and 19.3 per cent below the close two sessions earlier |
| EXCELLENCE, Phase 2/3 | Paediatric Rett, 5–17; 92 enrolled, 77 analysed | Missed. Co-primary clinical-impression endpoint not met. Behaviour questionnaire at twelve weeks −4.61, p=0.063 — not significant, and labelled “ad-hoc” in the company’s own annual report | Jan. 2, 2024 | −35.1 per cent, $9.31 to $6.045 on 9.3 million shares |
The AD-004 problem, in the company’s own words. The trial had two co-primary endpoints under a multiplicity rule: success if each reached P<0.05, or if one reached P<0.025. The functional co-primary, ADCS-ADL, never reached significance — P=0.357. Anavex declared the trial successful on the cognitive endpoint plus a secondary under that rule. The European committee rejected the reasoning, and the quarterly report filed August 28, 2026 reports the finding against the company itself:
“The CHMP determined that our single pivotal Phase 2b/3 trial… did not meet its co-primary endpoints… while the ADAS-Cog13 cognitive endpoint showed a nominally significant result under our primary analysis, the ADCS-ADL functional endpoint did not reach statistical significance, which the CHMP concluded rendered the trial formally negative. The CHMP further found that the statistical analysis underlying the nominally significant ADAS-Cog13 result was not the analysis pre-specified in the study’s protocol or statistical analysis plan, but reflected changes to the analysis model, choice of covariates, and covariance structure made after the study was unblinded. Therefore, the CHMP concluded that this modified analysis constituted a post-hoc analysis that could not render the failed study successful.”
And the drift is visible without the regulator. The December 1, 2022 release reported −1.85 points at p=0.033. The published version reports −2.027 at P=0.008. Same trial, same patients, different model. A reader quoting “hit its primary endpoint at p=0.008” is quoting the analysis that was rejected.
Two secondary points for precision. On sidedness: the peer-reviewed paper reports the p-values with two-sided confidence intervals and the multiplicity rule is framed as a two-sided split, so they read as two-sided; the documented defect is not the sidedness but the post-unblinding model change. On subgroups: the analysis in patients carrying the wild-type target gene was prespecified, but the larger genetic analyses that generate the eye-catching figures — slowing of up to about 85 per cent, cognitive differences around −4.2 points at P=0.0005 — are derived from genome-wide association work and were not part of the registration case the committee assessed. They are hypothesis-generating, and the page treats them that way.
What the extension study adds is the strongest remaining argument. ATTENTION-AD is a delayed-start design, which is the conventional way to test whether an effect is disease-modifying rather than symptomatic, and at week 192 it reported separation on both cognition and function. It is open-label, so it is not a controlled comparison — but it is the dataset a new Phase 3 would be designed to confirm, and it is the reason the European committee wrote design advice rather than closing the file.
The withdrawal assessment report the EMA published after the application was withdrawn (EMA/CHMP/130428/2026) sets out the safety and quality findings behind the refusal recommendation of December 11, 2025. In study ANAVEX2-73-AD-004, 108 participants on blarcamesine (32.2%) discontinued because of adverse events, against 12 on placebo (7.1%); the rate was 39.9% at 50 mg and 24.6% at 30 mg. Dizziness was reported in 35.8% of blarcamesine patients against 6.0% on placebo during the titration phase, and in 46.3% against 8.9% across the study as a whole. On quality, the committee raised a major objection because the formation of nitrosamine impurities could not be ruled out. The EMA also considered the safety database insufficient and the product not eligible for conditional approval. Any new Phase 3 would have to answer the tolerability question as well as the efficacy one. Source · EMA page
The same EMA assessment also questioned how missing data were handled. Its discussion notes baseline imbalances, while acknowledging adjustment for baseline values, and says the tipping-point analysis did not establish robustness because the analysis population required attendance at a post-baseline visit. The regulator regarded the biomarker findings as exploratory and did not accept them, individually or collectively, as substitutes for demonstrated clinical benefit. The nitrosamine objection concerned unresolved testing evidence: the applicant said testing found no risk, but had not supplied the actual results or adequate supporting documentation. That unresolved objection is not proof that contamination was detected. EMA assessment, pages 21–22 and 78.
| Item | June 30, 2026 |
|---|---|
| Cash and cash equivalents | $118.3M (from $102.6M at the September 2025 year end) |
| Working capital | $112.4M ($120.1M current assets against $7.7M current liabilities) |
| Total stockholders’ equity | $112.4M |
| Accumulated deficit | $385.6M |
| Debt | None. No borrowings, no notes, no convertibles, no term loan |
| Leases | Office space only, initial term twelve months or less — no right-of-use asset and no lease liability, cost $112 thousand over nine months |
| Operating cash used, nine months | $20.687M → $2.30M a month on average |
| Financing cash, nine months | +$36.436M, all from the at-the-market programme, all in the December quarter |
| Investing cash | Zero, both periods |
The nine-month average hides the trend. Derived from the disclosed quarter-end balances, the burn runs roughly $7.3 million in the December quarter, $4.3 million in the March quarter and $9.1 million in the June quarter — the last of those with no financing at all, so about $3.0 million a month, loaded with proxy-contest, special-committee and litigation cost.
At that rate $118.3 million is roughly three years of cash. The company guides to “mid to late fiscal 2028”, which is nearer two years, implying it is budgeting a step up to something like $4.5–5.5 million a month as Phase 3 work starts. That gap between the arithmetic and the guidance is the clearest signal in the filings about what the company expects to spend.
The runway guidance was cut once, and the timing is the tell. The fiscal 2025 annual report of November 25, 2025 gave no figure at all, only that working capital would be “sufficient to meet the Company’s working capital requirements beyond the next 12 months.” On February 9, 2026 the company said “an approximate cash runway of more than 3 years.” On July 30, 2026 that became “expected to fund operations into mid-to-late fiscal 2028,” repeated on August 25 — roughly a year shorter, even though reported burn had fallen year on year and the at-the-market programme had already been tapped. The cut came at the first release published after the chief executive’s termination.
There is no going-concern qualification and no substantial-doubt conclusion. The June quarterly report says management believes working capital is “sufficient to meet the Company’s working capital requirements beyond the next 12 months after the date that these… financial statements are issued.” Generic going-concern language appears in the risk factors, as it does for any pre-revenue issuer; that is not an auditor or management conclusion and should not be reported as one.
The June quarter’s $7.8 million of net income is an accounting artifact, not a turnaround. General and administrative expense printed at negative $2.0 million and research and development at negative $4.7 million, because $17.4 million of previously recognised stock-based compensation was reversed — $15.5 million on the termination of employees, “primarily our former CEO”, and $1.9 million on milestone-based options the company determined will never vest. Earnings per share came out at $0.08. The nine-month net loss of $3.2 million, against $36.6 million a year earlier, has the same cause. No cash changed hands in either direction. Anyone reading a screen that shows Anavex as profitable is reading a forfeiture, and the cash-flow statement is the only line that describes the business.
Two years of share-count history, and the striking thing is how little of it there is.
| Date | Shares outstanding |
|---|---|
| September 30, 2024 | 84,795,517 |
| September 30, 2025 | 86,668,521 |
| November 24, 2025 | 89,348,107 |
| December 31, 2025 | 92,671,758 |
| June 30, 2026 | 92,696,842 |
| August 28, 2026 (latest) | 92,696,842 |
Two-year dilution is about 9.3 per cent, and essentially all of it happened in a single quarter — October to December 2025, the quarter of the negative trend vote. Since December 31, 2025 the share count has moved by 25,084 shares in total.
The at-the-market programme is live but switched off. The sales agreement signed July 25, 2025 with TD Securities carries $150.0 million of capacity at a commission of up to 3 per cent. The company sold 6,026,237 shares for $36.4 million net, all of it in the December quarter at an implied average around $6.20 a share gross, and then stopped: “The Company suspended sales under the 2025 Sales Agreement following formation of the Special Committee.” About $103.2 million of capacity remains, the figure the company discloses at both March 31 and June 30, 2026, after $9.2 million net sold under the same agreement in fiscal 2025 and $36.4 million net in the December quarter. And the suspension is no longer the company’s to reverse. From the same quarterly report, verbatim: “We will be unable to make sales under the 2025 Sales Agreement after we file our next Annual Report on Form 10-K due to our loss of Form S-3 eligibility for the untimely filing of our Quarterly Reports… We will be unable to regain eligibility to use Form S-3 until we have timely filed all reports specified under Form S-3 for the preceding 12 calendar months.” So the annual report due by December 29 does not only carry an accounting opinion: it closes the facility, and it cannot reopen before roughly late 2027.
The older equity line — a $150 million purchase agreement signed in February 2023 — expired on February 3, 2026, having produced $11.3 million of cash in fiscal 2024 plus 75,000 commitment shares in 2023, and nothing thereafter. The shelf registration is $300 million, effective from July 2025 and therefore lapsing around July 2028; the at-the-market programme sits under it. There has been no underwritten offering, no private placement, no registered direct and no convertible in the period.
There are no warrants. The word does not appear in the June 2026 quarterly report outside the boilerplate definition of beneficial ownership. On a small-cap biotech that is unusual and worth saying plainly: there is no warrant overhang, no reset mechanism, and no variable-share instrument of the kind that turns a cheap financing into a much larger issue.
| Options | Weighted-average exercise price | |
|---|---|---|
| Outstanding, September 30, 2025 | 14,961,583 | $7.25 |
| Forfeited or cancelled, nine months | (6,019,249) | $8.27 |
| Outstanding, June 30, 2026 | 8,982,250 | $6.45 |
| Exercisable, June 30, 2026 | 7,754,420 | $5.96 |
Aggregate intrinsic value is $149,304 — on nine million options. Against a $2.02 close the weighted-average strike of $6.45 is more than three times the share price, The lowest strike in the 2026 Forms 4 is $5.36, though the quarterly report’s own table runs down to a $2.30 band. The 6.0 million forfeiture at an average $8.27 is the former chief executive’s awards and those of other departed employees. One tranche of 2,999,366 options sits between $2.30 and $5.00 at a $2.99 average, and that is the only part of the book within reach of the current price. Remaining capacity under the 2022 plan is 14,007,678 shares — a larger overhang than the entire options book.
And the board election reset the vesting. Because three directors were first elected “in connection with an actual or threatened proxy contest,” they are excluded from the definition of incumbent directors, leaving the incumbents in a minority. That satisfied the board-change test under the 2015, 2019 and 2022 incentive plans, so on September 24, 2026 “all outstanding and unvested awards granted under the Incentive Plans… immediately became fully vested and exercisable” — including performance awards whose milestones were never met, and including the clause in the principal financial officer’s own employment agreement. Management defeated the activist and accelerated its own equity in the same vote. All of it is far out of the money, so the cash consequence is nil; the governance signal is not.
On authorised capital there is no constraint: 200,000,000 common shares authorised against 92,696,842 outstanding, so 46.3 per cent used, plus 10,000,000 preferred with none issued. The limit on issuance here is the shelf and the company’s own decision to keep the facility suspended, not the charter.
There are two executive officers: Terrie Kellmeyer, interim chief executive since May 4, 2026, four days after the termination, previously head of clinical development; and Sandra Boenisch, principal financial officer and treasurer, who signs the filings. There is no permanent chief executive, no officer titled chief financial officer, no chief medical officer and no chief operating officer.
Departures in 2026: Christopher Missling, president and chief executive, terminated for Cause on April 30, 2026 by a special committee of independent directors; and Felix Lauscher, chief operating officer from March 1 and gone by May 11 — ten weeks, forfeiting 45,833 of 50,000 options. The $17.4 million of compensation reversals “associated with the termination of employees, primarily the former Chief Executive Officer” implies further departures that the filings do not name individually.
What is finished. The 2024 shareholder class action over Rett syndrome disclosures was dismissed in June 2025, and on June 26, 2026 the Second Circuit affirmed the dismissal, including denial of leave to amend; the plaintiff did not seek rehearing. Both derivative suits that had been stayed behind it were dismissed by stipulation in August 2026. No amount was ever recorded, “as we believe that it is not probable that any loss will occur.”
What is live, and unquantified. In June 2026 the company received an arbitration demand from the former chief executive asserting he was wrongfully terminated for Cause and seeking relief for “breach of contract, declaratory relief, and defamation” — cash severance, acceleration of equity awards, accrued compensation, legal fees and damages. The company “categorically denies any wrongdoing,” and states that “at this early stage of the proceedings, the Company cannot reasonably estimate any potential loss, or range of loss.” The definitive proxy describes without-Cause cash severance as three times the sum of annual salary and the average annual bonus for the last three completed calendar years. Its hypothetical September 30, 2025 calculation is $2.8 million, separate from equity acceleration and other benefits. This is a contractual scenario, not an awarded or admitted liability in the current dispute. On July 6, 2026 he also filed a summons in New York alleging breach of fiduciary duty against four named directors, derivatively on the company’s behalf; the company expects to be named a nominal defendant.
What is new and unverified. A securities class action was announced by plaintiffs’ firms on September 29–30, 2026, said to be filed in the Southern District of New York, with a class period of November 26, 2025 to August 28, 2026 and a lead-plaintiff deadline of November 30, 2026, alleging concealment of inadequate internal controls and of regulatory risk arising from the former chief executive’s conduct. We could not verify it at docket level — no case number, judge or docket entry was obtained — and it appears in no company filing, the June quarterly report predating it by a month. Reported here as the firms’ claims.
A deficiency notice arrived May 20, 2026 for the late March-quarter report; a compliance plan was submitted July 20; both late reports were filed August 28; and the exchange confirmed compliance regained on September 2, 2026. It was a filing-timeliness matter, not a price or market-value matter, and at $2.02 no price-based listing requirement is in play.
| Metric | Value |
|---|---|
| Close | $2.02, down 14.41 per cent from $2.36 |
| Session range, from a $2.38 open | $1.89–$2.38 — opened at the high, closed near the low |
| Volume | 2,965,136 against a three-month average of 899,815 — 3.3 times |
| Market value | ~$187.2M on 92,696,842 shares |
| Enterprise value, net of cash | ~$68.9M |
| Institutional ownership | 46.65 per cent, 43,246,056 shares across 222 holders, from lagged quarterly filings — net sellers over the period |
| Insider ownership | 5.71 per cent, eight people, including options exercisable within sixty days |
| Short interest, September 15 settlement | 14,333,378 shares = 15.46 per cent of outstanding, 25.1 days to cover |
The 14.4 per cent fall on September 30 tracks the class-action notices of the previous day, not any company disclosure. On the short side the shape matters more than the level: the position ran at 18–19 million shares through May, fell by about 5 million between March and June — that is, through the European withdrawal and the chief executive’s termination — and has been flat to slightly higher since. The crowd that was positioned for the collapse has largely taken the money, and what is left is 25 days of average volume on a $187 million company sitting on $118 million of cash.
The largest individual insider holder is still the terminated chief executive, at 3,719,665 shares or 3.93 per cent, on the proxy’s July 30, 2026 ownership date, the day before the July 31 record date — while suing the company. Three of the directors hold no shares at all. Above 5 per cent there are two institutions, BlackRock at about 7.2 per cent and a Vanguard entity at 5.03 per cent; the main Vanguard Group filing went to zero in a March 2026 amendment, which gives the cause as a January 12, 2026 internal realignment that moved the holding into Vanguard Capital Management’s own filing rather than a disposal. No Schedule 13D was filed in 2026 by anyone, including the activist — who held 337,663 shares, about 0.36 per cent of the company, which is why no such filing exists and why the dissident slate topped out at 14.5 million votes.
There was not a single open-market purchase and not a single open-market sale by any insider in all of 2026. Every 2026 Form 4 is an option grant or a vesting event. Two are worth noting. On January 6, 2026 options over 125,000 shares vested to the chief executive and 12,500 to the principal financial officer because a performance milestone described as a second regulatory dialogue for blarcamesine was certified as met — seven weeks after the negative trend vote. And on September 24, 2026 the principal financial officer’s four tranches totalling 95,000 performance options at strikes from $5.36 to $10.09 vested purely on the change of control. All are far out of the money against $2.02.
The exchange’s own feed lists three covering analysts and no price-target record at all. The reviewed secondary aggregators report three 2026 actions; the original broker notes have not been verified: $20 on February 10, $24 on March 31, and an initiation of coverage at Buy with a $20 target on May 4, 2026, four days after the termination for Cause and before the auditor’s reversal, the late filings and the proxy contest. No later action is included in the reviewed screens. Some screens still carry targets of $42 to $46 dated 2025. The targets in the reviewed screens predate major subsequent developments and are not a verified current consensus; this page adopts none of them.
| Window | Event | Status |
|---|---|---|
| By December 29, 2026 | Fiscal 2026 annual report — and the auditor’s opinion on whether the internal-control failure is remediated at September 30, 2026. Last year’s was filed November 25 | Statutory. The nearest dated event, the real binary, and the filing that closes the at-the-market facility |
| Due now | Last patient visit in the drug-interaction study, guided “by the end of September” 2026 | Unconfirmed at October 1 |
| Due now | Fragile X investigational new drug submission, guided for September 2026 | Unconfirmed. A submission starts a thirty-day clock |
| Not dated | FDA meeting on adding paediatric patients to the Rett Phase 3 — the agency granted the request on September 9 | Granted, not scheduled. No date public |
| Not dated | Adult Rett Phase 3 start, about 170 participants | Protocol approved, no start date, no registry entry |
| Not dated | Alzheimer’s Phase 3 — European design advice adopted June 2026, FDA protocol discussion ongoing | Design stage. A European Phase 3 “is not being pursued at this time” |
| November 30, 2026 | Lead-plaintiff deadline in the class action announced September 29 | Reported by plaintiffs’ firms; not docket-verified here |
| Not dated | Arbitration with the former chief executive, and the derivative claim against four directors | Live. No reserve, no range, no hearing date disclosed |
| Not dated | A permanent chief executive | Interim since April 30, 2026 |
Anavex is trading at roughly $69 million of enterprise value — $187 million of market capitalisation less $118.3 million of cash, with no debt, no warrants, no multi-year lease and no going-concern language. That is a genuinely unusual balance sheet for a company this damaged, and it is the whole constructive case. Four programmes carry designations, the European committee has written design advice for a new Alzheimer’s Phase 3, the Rett protocol is approved, the old litigation is finished and the listing issue is cured.
What the page has to set against that is everything the last eleven months did. The pivotal trial’s functional co-primary failed, and the cognitive result that the market still quotes rests on an analysis the regulator found was changed after unblinding — a finding the company now prints in its own filing. The European application was not rejected so much as withdrawn ahead of a rejection, and the assessment report that followed recommends refusal. The chief executive was removed for Cause, the auditor reversed itself on internal controls and named tone at the top, two reports were filed late, and the man who ran the company is both its largest individual shareholder and its counterparty in an arbitration whose exposure the company will not estimate.
The practical position is that the cash is not the constraint and the calendar is. There is no application, no enrolling trial, no readout and no permanent chief executive, and the nearest dated event is a statutory annual report whose news value is an accounting opinion. For a trader that cuts both ways: nothing dated means nothing to underwrite, and it also means the next real date — a Phase 3 start, a Fragile X filing, a clean controls opinion — arrives into a share price that currently assumes none of them. The one number to keep in view is the $103.2 million of unused at-the-market capacity, because it is larger than the entire enterprise value and, on the company’s own statement, it stops being available the moment the annual report is filed.
None of the above is a recommendation, a target or a view on the share price. It is a description of what is documented, what is guided, and what the record does not say.
Method, and what is not verified. Financial and capital-structure figures come from the Form 10-Q for the quarter ended June 30, 2026 and the fiscal 2025 annual report with its August 2026 amendment; the fiscal year ends September 30, so no fiscal 2026 annual report exists yet. Regulatory and clinical facts come from those filings and from the 2026 Forms 8-K read with their exhibits. Market figures come from the exchange’s own series. The quarterly burn figures are derived from the disclosed quarter-end cash balances and are labelled as calculations, as is the enterprise value. The following are not established on the public record: docket-level verification of the class action announced on September 29–30, 2026, whose notices give no case number and which appears in no company filing; any current analyst price target from a primary source, the exchange’s own feed carrying no target record and the historical target figures coming from secondary aggregators; a start date or registry entry for the adult Rett Phase 3; a date for the FDA meeting granted on September 9, 2026; confirmation that the Fragile X investigational filing was submitted or that the drug-interaction study completed, both guided for September 2026; any estimate of loss in the arbitration, which the company declines to give; and the identity of employees beyond the two named officers whose departures produced the $17.4 million compensation reversal. Anavex discloses no float figure; the estimate used here is derived from the share count less shares actually held by directors and officers.
Educational and editorial content only. This report is not personalised financial advice, a solicitation, or a recommendation to buy, sell or hold any security. Biotech and small and mid-cap stocks can be extremely volatile and may result in partial or total loss of capital. Regulatory outcomes, trial results, litigation, financing availability, dilution and management changes all remain uncertain.
Balance-sheet and income-statement figures are those reported for the quarter ended June 30, 2026 and are historical. Price, range, volume and performance figures are at the September 30, 2026 close. Short-interest figures are as of the September 15, 2026 settlement date and are published with a lag. Institutional-ownership figures derive from lagged quarterly filings. Published analyst targets are third-party views, dated, and adopted by nobody here. Market prices are indicative and may differ materially from the opening or closing price on any given day.
No. The marketing application was withdrawn on March 25, 2026, before the re-examination the company had requested could complete, “following feedback from the EMA’s CHMP indicating that it would not be in a position to issue a positive opinion.” In June 2026 the committee published a withdrawal assessment report concluding the overall benefit-risk was negative and recommending refusal of even a conditional authorisation. There is no application and no pending opinion. Any 2026 write-up giving a committee decision date is recycling the timeline from before the negative trend vote of November 14, 2025.
Not both of them. The trial had two co-primary endpoints, and the functional one, ADCS-ADL, came in at P=0.357 — not significant. The cognitive endpoint is the one usually quoted, and the company’s own quarterly report filed August 28, 2026 records the regulator’s conclusion that the model behind it “was not the analysis pre-specified in the study’s protocol or statistical analysis plan” but reflected “changes to the analysis model, choice of covariates, and covariance structure made after the study was unblinded,” and therefore “constituted a post-hoc analysis that could not render the failed study successful.” The drift is visible on the face of the disclosures: the December 1, 2022 release reported −1.85 points at p=0.033; the published version reports −2.027 at P=0.008.
No. It has no FDA designation of any kind in Alzheimer’s — there is an investigational new drug filing opened in March 2026 and nothing more. The Orphan Drug, Rare Pediatric Disease and Fast Track designations are for Rett syndrome; there is a separate Orphan designation for Fragile X, and one for ANAVEX 3-71 in frontotemporal dementia.
Cash and equivalents were $118.3 million at June 30, 2026, up from $102.6 million at the September 2025 fiscal year end, with working capital of $112.4 million. There is no debt of any kind — no borrowings, no notes, no convertibles — and no multi-year lease liability. There is no going-concern qualification. The company guides that the cash will “fund operations into mid-to-late fiscal 2028,” revised down from “more than 3 years” stated in February 2026. Derived from the disclosed quarter-end balances, the June quarter burned about $9.1 million, roughly $3.0 million a month.
Because $17.4 million of previously recognised stock-based compensation was reversed when employees left, “primarily the former Chief Executive Officer.” That is why general and administrative expense printed at negative $2.0 million and research and development at negative $4.7 million, producing net income of $7.8 million, or $0.08 a share. No cash changed hands. The nine-month net loss of $3.2 million against $36.6 million a year earlier has the same cause. The cash-flow statement is the only line that describes the business.
A special committee of independent directors terminated Christopher Missling for Cause on April 30, 2026. Terrie Kellmeyer has been interim chief executive since. In June 2026 the company received an arbitration demand in which he asserts he was wrongfully terminated and seeks relief for breach of contract, declaratory relief and defamation — severance, equity acceleration, legal fees and damages. The company “categorically denies any wrongdoing” and says it “cannot reasonably estimate any potential loss, or range of loss.” On July 6, 2026 he also filed a derivative claim against four directors. He remains the largest individual insider holder at about 3.93 per cent.
On August 28, 2026 the company amended its fiscal 2025 annual report to state that internal control over financial reporting was not effective, and the auditor reversed its earlier unqualified opinion in writing. The stated cause, verbatim: the company “did not maintain effective Control Environment and Information and Communication elements of the COSO framework as the former CEO failed to set an appropriate tone at the top, including lack of transparency with the Board regarding regulatory, clinical and non-financial matters.” No financial statements were restated. Whether the weakness is reported as remediated at September 30, 2026 is the question the annual report due by December 29 answers.
About $103.2 million of a $150 million at-the-market programme, against a market value of roughly $187 million. The company sold 6,026,237 shares for $36.4 million net in the December 2025 quarter and then “suspended sales… following formation of the Special Committee.” More important than the suspension: the June quarterly report states the company “will be unable to make sales under the 2025 Sales Agreement after we file our next Annual Report on Form 10-K due to our loss of Form S-3 eligibility for the untimely filing of our Quarterly Reports,” and cannot regain eligibility until twelve months of reports have been filed on time. An older $150 million equity line expired unused on February 3, 2026. The shelf registration is $300 million, lapsing around July 2028. There are no warrants outstanding, and 200,000,000 shares are authorised against 92,696,842 outstanding.
No. This Stock Hub is informational and educational. It sets out dated facts, their sources and the scenarios they leave open, and it says where the record is silent. It does not recommend any action.
Every Merlintrader stock hub, catalyst update and market brief is published to Telegram the moment it goes live. No paywall, no spam, just the research.
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $AVXL or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, European Medicines Agency documents, company press releases, official trial registries and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.
